Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 13/20 | 0.54 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17459572 | 1.00 | TPH1 (0.54) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL34462086 | 0.87 | SLC7A5 (0.54) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31369650 | 0.83 | SLC7A5 (0.61) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL26966009 | 0.83 | SLC7A5 (0.61) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL16555365 | 0.82 | SLC7A5 (0.56) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL31370558 | 0.81 | SLC7A5 (0.62) | TPH1SLC7A5PTGS1ALPIPKM | |
| SCHEMBL17468539 | 0.80 | TPH1 (0.40) | TPH1SLC7A5 | |
| SCHEMBL28526417 | 0.80 | TPH1 (0.40) | TPH1SLC7A5 | |
| SCHEMBL17459581 | 0.79 | CXCR1 (0.42) | TPH1 | |
| SCHEMBL17459579 | 0.79 | CXCR1 (0.42) | TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519407-B1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | RECEPTOS LLC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-11066395-B2 | Dimethylaminoethanol salt of a GLP-1 receptor modulator | RECEPTOS LLC (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3172199-B1 | PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-20200131164-A1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | RECEPTOS LLC | 2020-04-30 | — | — | US | disclosed |
| EP-3519407-A1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | Celgene International II Sàrl (CH) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018064476-A1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | CELGENE INTERNATIONAL II SARL (CH) | 2018-04-05 | — | — | WO | disclosed |
| US-9839664-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-12-12 | — | — | US | disclosed |
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-08-03 | — | — | US | disclosed |
| EP-3172199-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | Receptos, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9474755-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SARL (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-02-11 | — | — | US | disclosed |
| WO-2016015014-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216392-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | TPH1 1203/4885SLC7A5 3743/4885PTGS1 1369/4885 |
| US-20200131164-A1 | DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR MODULATOR | GLP1R, GIPR, GPR119 | TPH1 287/4885SLC7A5 2699/4885PTGS1 1106/4885 |
| US-11066395-B2 | Dimethylaminoethanol salt of a GLP-1 receptor modulator | GLP1R, GIPR, GPR119 | TPH1 287/4885SLC7A5 2699/4885PTGS1 1106/4885 |
| US-20160038487-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | TPH1 1203/4885SLC7A5 3743/4885PTGS1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.